Neogenomics (NEO) Net Cash Flow (2010 - 2026)

Neogenomics has reported Net Cash Flow for 17 years, with the latest figure at -$13.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 35.27% year-over-year to -$13.5 million; the trailing twelve-month figure through Mar 2026 stood at -$200.1 million (down 1500.92% YoY), and the FY2025 full-year result was -$207.4 million, down 945.68% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$13.5 million, down from -$4.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $36.2 million in Q4 2023, with the low at -$191.4 million in Q2 2025.
• Historically, Net Cash Flow has averaged -$10.0 million across 5 years, with a median of -$2.9 million in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow jumped 1330.45% — and 2025, when it sank 926.11%.
• Neogenomics' Net Cash Flow stood at -$2.9 million in 2022, then jumped by 1330.45% to $36.2 million in 2023, then sank by 86.15% to $5.0 million in 2024, then plunged by 190.26% to -$4.5 million in 2025, then sank by 197.4% to -$13.5 million in 2026.
• The last three Net Cash Flow figures came in at -$13.5 million (Q1 2026), -$4.5 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.